Bronchitis - Pipeline Review, H2 2016

Date: September 28, 2016
Pages: 59
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B19587FB1E2EN
Leaflet:

Download PDF Leaflet

Bronchitis - Pipeline Review, H2 2016
Bronchitis - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Bronchitis - Pipeline Review, H2 2016’, provides an overview of the Bronchitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Bronchitis
  • The report reviews pipeline therapeutics for Bronchitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Bronchitis therapeutics and enlists all their major and minor projects
  • The report assesses Bronchitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Bronchitis
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bronchitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bronchitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Bronchitis Overview
Therapeutics Development
Pipeline Products for Bronchitis - Overview
Bronchitis - Therapeutics under Development by Companies
Bronchitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Bronchitis - Products under Development by Companies
Bronchitis - Companies Involved in Therapeutics Development
AstraZeneca Plc
DBV Technologies S.A.
F. Hoffmann-La Roche Ltd.
Hyundai Pharmaceutical Co., Ltd.
Invion Limited
Kyorin Pharmaceutical Co., Ltd.
Mucosis B.V.
Orbis Biosciences Inc
Recipharm AB
Bronchitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
alteplase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-9668 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erdosteine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOB-051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KRPAM-1977X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nadolol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitric oxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prednisone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SynGEM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bronchitis - Dormant Projects
Bronchitis - Discontinued Products
Bronchitis - Product Development Milestones
Featured News & Press Releases
Nov 10, 2015: Recipharm secures €25 million contract for Erdosteine API with Daewoong Pharmaceutical
Nov 10, 2015: Recipharm secures €25 million contract for Erdosteine API with Daewoong Pharmaceutical
Oct 07, 2015: EVP R&D Dr Mitchell Glass discusses with BRR media data from the Phase 2 clinical trial of INV102 (nadolol) in Smoking Cessation
Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
Apr 21, 2015: Advanced Inhalation Therapies to Present AIT-RSV Clinical Data at Two Upcoming Medical Meetings
Jan 23, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants
Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL
Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Bronchitis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Bronchitis - Pipeline by AstraZeneca Plc, H2 2016
Bronchitis - Pipeline by DBV Technologies S.A., H2 2016
Bronchitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Bronchitis - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
Bronchitis - Pipeline by Invion Limited, H2 2016
Bronchitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
Bronchitis - Pipeline by Mucosis B.V., H2 2016
Bronchitis - Pipeline by Orbis Biosciences Inc, H2 2016
Bronchitis - Pipeline by Recipharm AB, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Bronchitis - Dormant Projects, H2 2016
Bronchitis - Dormant Projects (Contd.1), H2 2016
Bronchitis - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Bronchitis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

AstraZeneca Plc
DBV Technologies S.A.
F. Hoffmann-La Roche Ltd.
Hyundai Pharmaceutical Co., Ltd.
Invion Limited
Kyorin Pharmaceutical Co., Ltd.
Mucosis B.V.
Orbis Biosciences Inc
Recipharm AB
Skip to top


Bronchitis - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 53 pages
Microbio Co., Ltd. - Product Pipeline Review - 2014 US$ 1,125.00 Jul, 2014 · 28 pages
Genfit SA - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 38 pages

Ask Your Question

Bronchitis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: